Delivered by Brandon BioCatalyst, CUREator is backed by the Australian Federal Government’s Medical Research Future Fund. The MRFF’s $80 million Medical Research Commercialisation Initiative aims to support early-stage health and medical research and innovation in Australia through to proof-of-concept and beyond, providing opportunities for commercialisation. CUREator is responsible for managing a $40m portion of this fund, dedicated to supporting novel therapeutics and preclinical medical research. CUREator has an additional $3 million in funding from Australia’s national science agency, CSIRO, to support Australia’s health security and protect against emerging infectious diseases and pandemics.
Australia’s national biotech incubator
CUREator is a national biotechnology incubator run by Brandon BioCatalyst aimed at supporting the development of Australian biomedical innovations. CUREator is a nationwide incubator program that provides grant funding for successful preclinical medical research and medical innovation projects, health security innovations and clinical-stage novel therapeutics. Funding is provided with clear milestone-driven tranches and help is provided to guide development of these assets and maximise their chance of success. We like to think about the program as investors providing grant funding like an investor.
CUREator aims to identify early-stage biomedical technologies that require targeted funding to support their advancement to the point that they are investment or partnering ready.
The preclinical stream supports preclinical medical research or medical innovation projects based in Australia with commercial potential.
CUREator’s clinical stream supports the clinical development of novel, clinical stage drug therapies to treat disease. Opportunities that successfully receive funding through this stream, will also have the opportunity to apply for matching investment from Brandon Capital or third-party funding.
The CSIRO funding allows CUREator to launch a new and unique health security stream which will support promising projects for over two years across fields including emerging infectious diseases and pandemics research, and therapies targeting chemical, biological and radiological threats.
Applications will be assessed using the established Brandon BioCatalyst processes and committees, together with independent panel members to ensure robust and balanced selections.
Successful applicants must perform the research in Australia (where possible); and funding must be provided to an Australian company/institution. Applicants choosing the Preclinical or Clinical Stream will be required to form a for-profit entity (company) prior to receiving grant award. Applicants may still apply for CUREator funding if a company does not yet exist – CUREator may assist successful applicants in establishing a legal vehicle immediately prior to award.
We welcome and encourage applications from individuals with diverse backgrounds, including underrepresented genders* and diverse lived experiences (including those living with disability, rural and regional locations, neurodiversity, culturally diverse backgrounds and of Aboriginal and Torres Strait Islander heritage).
*This includes cis women, non-binary people, and those who are otherwise marginalised.
Expressions of Interest (EOI) for Round Two are now open. Application guidelines can be found here. EOI applications close Monday 29th August at 5:00pm AEST. To apply, visit www.cureator.awardsplatform.com
For more information about Round 1 awardees, read here.
CUREator National Virtual Roadshow
In an effort to keep our attendees and staff safe due to the high COVID burden across Australia currently, CUREator has decided to host meetings as part of the national roadshow virtually.
CUREator will now meet with prospective applicants for Round 2 online. Round 2 Applicants interested in applying for CUREator funding are encouraged to arrange a brief private meeting with the CUREator team members. Discussions should be centred around helping applicants position their proposal towards commercially orientated outcomes or to seek additional clarity related to funding requirements and streams. Please note during these meetings the CUREator team will not be able to give project specific advice and all advice will be general in nature.
The CUREator team invites those interested in applying for CUREator Round 2 funding to contact us at email@example.com to book a slot to meet with the CUREator team. Meeting time will be a maximum of 20 minutes and we ask team members to please consult one another prior to arranging a meeting to ensure there isn’t any duplication of meetings. The CUREator team encourages interested parties to propose 3 suitable times during the corresponding open dates given below and the CUREator team will endeavour to arrange a meeting. To direct the conversation prior to the scheduled meeting teams should pre-submit any question(s) they wish to address to steer meeting discussions including the intended stream they will be seeking funding from.
All streams will have access to Brandon Capital and Brandon BioCatalyst’s extensive experience in developing biomedical technologies. Brandon Capital will provide successful applicants with hands-on support and access to their global network of experts.
In addition, grant recipients can expect to benefit from connections to pharmaceutical companies, local and international venture capital firms and institutional investors. Through these networks, CUREator will assist projects and companies seeking follow-on funding through Brandon Capital or corporate partnerships. Grant recipients will also be able to co-locate at the Brandon BioCatalyst offices across the country or at Brandon BioCatalyst’s incubators in Melbourne and Sydney.
For more information, please contact firstname.lastname@example.org